Successful unrelated allogeneic stem cell transplantation after treatment of lymphoid blast crisis CML with imatinib and imatinib-containing conditioning regimen in a 16-year-old male

Bone Marrow Transplantation

Volumn 32, Issue 5, 2003, Pages 541-542

  Koch, M ^a   Lang, P ^a   Bader, P ^a   Kreyenberg, H ^a   Schumm, M ^a   Scheel Walter, H ^a   Hochhaus, A ^b   Niethammer, D ^a   Greil, J ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; METHOTREXATE; PREDNISOLONE; THYMOCYTE ANTIBODY; VINCRISTINE;

ADOLESCENT; ALLOTRANSPLANTATION; BLAST CELL CRISIS; CANCER REGRESSION; CEREBROSPINAL FLUID ANALYSIS; CHEMOTHERAPY INDUCED EMESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG EFFICACY; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MALE; NAUSEA; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADOLESCENT; BLAST CRISIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0141478752     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704167     Document Type: Letter

References (12)

1. Derderian PM, Kantarjian HM, Talpaz M et al. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. Am J Med 1993; 94: 69-74.
2. Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042.
3. Kantarjian HM, Talpaz M, Keating MJ et al. Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosomepositive chronic myelogenous leukemia. Cancer 1991; 68: 1201-1207.
4. Sacchi S, Kantarjian HM, O'Brien S et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 1999; 86: 2632-2641.
5. Walters RS, Kantarjian HM, Keating MJ et al. Therapy of lymphoid and undifferentiated chronic myelogenous leukemia in blast crisis with continuous vincristine and adriamycin infusions plus high-dose decadron. Cancer 1987; 60: 1708-1712.
6. Gabert J, Beillard E, Bi W et al. European standardization and quality control program of real time quantitative RT-PCR analysis of fusion gene transcripts for minimal residual disease detection in leukemia patients. Blood 2000; 96 (Suppl.): 311a.
7. Kreyenberg H, Hölle W, Möhrle S et al. Quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection: the Tübinger experience. Leukemia 2003; 17: 237-240.
8. Suttorp M, Lion T, Creutzig U et al. [Treatment of chronic myeloid leukemia in children and adolescents - concept of the multicenter pilot study CML-ped.]. Klin Padiatr 1996; 208: 242-249.
9. Sawyers CL, Hochhaus A, Feldman E et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530-3539.
10. Wassmann B, Klein SA, Scheuring U et al. Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation. Bone Marrow Transplant 2001; 28: 721-724.
11. Topaly J, Fruehauf S, Ho AD, Zeller WJ. Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning. Br J Cancer 2002; 86: 1487-1493.
12. Fang G, Kim CN, Perkins CL et al. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood 2000; 96: 2246-2253.